Metformin outperforms glipizide in preventing CVD events in diabetes

01/2/2013 | Modern Medicine

Long-term metformin treatment was associated with fewer cardiovascular events than glipizide therapy in type 2 diabetes patients with a history of coronary artery disease, according to a study in Diabetes Care. Data on 304 patients showed 35.1% of glipizide-treated patients experienced cardiovascular events at five years, compared with 25% of metformin-treated patients.

View Full Article in:

Modern Medicine

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX